I 

113TH CONGRESS 

2D SESSION H. R. 4746 

To amend the Public Health Service Act to establish a program of research 

regarding the risks posed by the presence of dioxin, synthetic fibers, 

chemical fragrances, and other components of feminine hygiene products. 

IN THE HOUSE OF REPRESENTATIVES 

MAY 28, 2014 

Mrs. CAROLYN B. MALONEY of New York (for herself, Mr. FARR, and Ms. 

MOORE) introduced the following bill; which was referred to the Committee on Energy and Commerce 

A BILL 

To amend the Public Health Service Act to establish a program of research regarding the risks posed by the presence of dioxin, synthetic fibers, chemical fragrances, and 

other components of feminine hygiene products. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Robin Danielson Act 

5 of 2014’’. 

6 SEC. 2. FINDINGS. 

7 The Congress finds as follows: 


jbell on DSK4SPTVN1PROD with BILLS
2 

•HR 4746 IH

1 (1) Feminine hygiene products are widely used 

2 by women in the United States today, but there is 

3 not enough research on the components of these 

4 products. 

5 (2) Women may be exposed to substances in 

6 tampons and other menstrual products for as long 

7 as 60 years over the course of their reproductive 

8 lives. The average woman may use as many as 

9 16,800 tampons in her lifetime. A woman on meno10 pausal hormone therapy may use as many as 24,360 

11 tampons in her lifetime. 

12 (3) Trace amounts of dioxins can be found in 

13 tampons or other feminine hygiene products. The 

14 Environmental Protection Agency and the Inter15 national Agency for Research on Cancer, an arm of 

16 the World Health Organization, have concluded that 

17 dioxins are a probable human carcinogen (cancer18 causing agent). 

19 (4) The Food and Drug Administration (re20 ferred to in this section as the ‘‘FDA’’) has histori21 cally relied on data provided by manufacturers of 

22 feminine hygiene products in determining product 

23 safety. 

24 (5) Although the FDA currently requires tam25 pon manufacturers to routinely monitor dioxin levels 


jbell on DSK4SPTVN1PROD with BILLS
3 

•HR 4746 IH

1 in raw materials and finished tampons, this informa2 tion is not readily available to the public. The FDA 

3 should consider whether to expand regulation to in4 clude other types of feminine hygiene products and 

5 a broader list of contaminants. 

6 SEC. 3. RESEARCH ON DIOXIN AND OTHER POTENTIALLY 

7 HARMFUL COMPONENTS OF FEMININE HY8 GIENE PRODUCTS. 

9 Part F of title IV of the Public Health Service Act 

10 (42 U.S.C. 287d et seq.) is amended by adding at the end 

11 the following section: 

12 ‘‘SEC. 486C. RESEARCH ON DIOXIN AND OTHER POTEN13 TIALLY HARMFUL COMPONENTS OF FEMI14 NINE HYGIENE PRODUCTS. 

15 ‘‘(a) RESEARCH.— 

16 ‘‘(1) IN GENERAL.—The Director of NIH, in 

17 collaboration with the Director of the Office, shall 

18 provide for the conduct or support of research to de19 termine the extent to which the presence of dioxins, 

20 synthetic fibers, chlorine, and other components, in21 cluding contaminants and substances used as fra22 grances, in tampons and other feminine hygiene 

23 products— 

24 ‘‘(A) poses any risks to the health of 

25 women who use the products, including risks reVerDate Mar 15 2010 05:51 Jun 03, 2014 Jkt 039200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H4746.IH H4746

jbell on DSK4SPTVN1PROD with BILLS
4 

•HR 4746 IH

1 lating to cervical cancer, endometriosis, infer2 tility, ovarian cancer, breast cancer, immune 

3 system deficiencies, pelvic inflammatory disease, 

4 toxic shock syndrome, and bacterial and yeast 

5 infections; and 

6 ‘‘(B) poses any risks to the health of chil7 dren of women who used such products during 

8 or before the pregnancies involved, including 

9 risks relating to fetal and childhood develop10 ment. 

11 ‘‘(2) REQUIREMENT REGARDING DATA FROM

12 MANUFACTURERS.—Research under paragraph (1) 

13 shall include research to confirm the data on tam14 pons and other feminine hygiene products submitted 

15 to the Commissioner of Food and Drugs by manu16 facturers of such products. 

17 ‘‘(3) DEFINITION.—For purposes of paragraph 

18 (1), the term ‘feminine hygiene products’ means 

19 tampons, pads, liners, cups, sponges, and similar 

20 products used by women with respect to menstrua21 tion or other genital-tract secretions. 

22 ‘‘(b) REPORTS.—Reports on the results of research 

23 under subsection (a) shall be periodically submitted to the 

24 Congress, the Commissioner of Food and Drugs, the Ad25 ministrator of the Environmental Protection Agency, and 


jbell on DSK4SPTVN1PROD with BILLS
5 

•HR 4746 IH

1 the Chairman of the Consumer Product Safety Commis2 sion. Such reports shall be made available to the public 

3 through the data system and clearinghouse program es4 tablished under section 486A, or through other appro5 priate means. 

6 ‘‘(c) AUTHORIZATION OF APPROPRIATIONS.—For the 

7 purpose of carrying out this section, there are authorized 

8 to be appropriated such sums as may be necessary for 

9 each of the fiscal years 2015 through 2019.’’. 

Æ 


jbell on DSK4SPTVN1PROD with BILLS